section name header

Pronunciation

ELB-as-vir/graz-OH-pre-vir

Classifications

Therapeutic Classification: antivirals

Pharmacologic Classification: NS5A inhibitors, protease inhibitors

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Elbasvir

Absorption: Well absorbed following oral administration.

Distribution: Extensively distributed to tissues.

Protein Binding: >99.9%.

Metabolism/Excretion: Partially metabolized by the CYP3A4 isoenzyme. >90% excreted in feces and <1% eliminated in urine.

Half-life: 24 hr.

Grazoprevir

Absorption: Well absorbed following oral administration.

Distribution: Extensively distributed to tissues.

Protein Binding: >98.8%.

Metabolism/Excretion: Partially metabolized by the CYP3A4 isoenzyme. >90% excreted in feces and <1% eliminated in urine.

Half-life: 31 hr.

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
elbasvir (PO)unknown3 hr24 hr
grazoprevir (PO)unknown2 hr24 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

GI: liver enzymes, abdominal pain, diarrhea, HEPATIC DECOMPENSATION/FAILURE, nausea.

Neuro: headache, insomnia.
Misc: fatigue, ANGIOEDEMA, hepatitis B virus reactivation.

Interactions

Drug-Drug:

Drug-Natural Products:

Route/Dosage

Patients with HCV genotype 1a infection should be tested for the presence of virus with NS5A resistance-associated polymorphisms prior to initiation of therapy to determine the most appropriate dosage regimen and duration of therapy

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Zepatier